fda drug shortage list tirzepatide GLP-1 No Longer on FDA's FDA reconsidering its decision to

The service can support cash-pay cross-border prescription options for patients without insurance when eligibility and jurisdiction allow

Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease

What is known about the cardiovascular safety of retatrutide in adults with obesity and type 2 diabetes, and how should it be used in patients with existing cardiovascular disease?

TRIUMPH-1 Phase 3 topline results: retatrutide in adults with obesity

Despite lowering disease biomarkers, Novo Nordisks semaglutide failed to buck the trend